glp-1 agonists for diabetes Glucagon-like peptide-1 (GLP-1) receptor are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 mellitus and #obesity. receptor agonists and GLP-1 and glucose-dependent insulinotropic GLP-1R and Diabetes
Description
doi: 10.1016/j.ejphar.2015.09.029 67 PajaresMRojo AIMandaGBoscLCuadradoA

Pediatr Diabetes

Specifically IPRA (0.13 mg/kg), PIO (330 mg/kg), IPRA (1 mg/kg) combined with PIO (10 mg/kg), or a vehicle were given orally to diabetic mice with NASH for 4 weeks

Prior to this several other anti-obesity drugs had also proven disappointing due to adverse effects such as cardiovascular problems, increased suicidal risk and enhanced drug dependence and abuse (Mller, Blher, Tschp, DiMarchi)

Am Psychol 75(2):235251 Gloy VL, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G et al (2013) Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials
